Testing times

Belief in the value of DNA sequence led to investment in the technology that made the Human Genome Project possible. But DNA sequences are not in themselves inventions, and gene variants and the conditions in which they cause disease are discovered and held by many stakeholders. So, if patents are t...

Full description

Saved in:
Bibliographic Details
Published inNature genetics Vol. 44; no. 5; p. 473
Format Journal Article
LanguageEnglish
Published New York Nature Publishing Group US 01.05.2012
Nature Publishing Group
Subjects
631/208/212
706/648/270
Agriculture
Animal Genetics and Genomics
Biomedical and Life Sciences
Biomedicine
Biotechnology industry
Breast cancer
Breast Neoplasms - genetics
Cancer
Cancer Research
Diagnosis
editorial
Federal court decisions
Female
Gene Function
Genes
Genetic Predisposition to Disease
Genetics
Germ-Line Mutation
Human Genetics
Humans
Identification and classification
Ovarian Neoplasms - genetics
Patent law
United States
Online AccessGet full text

Cover

More Information
Summary:Belief in the value of DNA sequence led to investment in the technology that made the Human Genome Project possible. But DNA sequences are not in themselves inventions, and gene variants and the conditions in which they cause disease are discovered and held by many stakeholders. So, if patents are to continue to provide incentives of benefit from genomics, they must be licensed for competition that is not a zero-sum game.
Bibliography:SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-4
ObjectType-Editorial-2
ObjectType-Commentary-1
ObjectType-Article-3
content type line 23
ISSN:1061-4036
1546-1718
1546-1718
DOI:10.1038/ng.2264